Novartis Kisqali adds one more year of survival benefit for

Basel: Pharma major, Novartis, has announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival...

Related Keywords

United States , Tennessee , Jeff Legos , Denisea Yardley , Sarah Cannon Research Institute At Tennessee Oncology , Breast Cancer Research Program , European Commission , Drug Administration , National Comprehensive Cancer Network , Novartis , Senior Investigator , Sarah Cannon Research Institute , Tennessee Oncology , Executive Vice President , Global Head , Clinical Benefit Scale , United States Food , Novartis News , Breast Cancer , Visceral Metastases , Kisqali , Ribociclib , Endocrine Therapy ,